Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Change in Acquisitions & Divestments (2016 - 2018)

Historic Change in Acquisitions & Divestments for Ironwood Pharmaceuticals (IRWD) over the last 10 years, with Q4 2018 value amounting to $19.9 million.

  • Ironwood Pharmaceuticals' Change in Acquisitions & Divestments fell 2847.57% to $19.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was $99.2 million, marking a year-over-year decrease of 7141.31%. This contributed to the annual value of $99.2 million for FY2018, which is 7141.31% down from last year.
  • Ironwood Pharmaceuticals' Change in Acquisitions & Divestments amounted to $19.9 million in Q4 2018, which was down 2847.57% from $16.8 million recorded in Q3 2018.
  • Over the past 5 years, Ironwood Pharmaceuticals' Change in Acquisitions & Divestments peaked at $133.8 million during Q1 2017, and registered a low of $13.9 million during Q2 2018.
  • For the 5-year period, Ironwood Pharmaceuticals' Change in Acquisitions & Divestments averaged around $58.1 million, with its median value being $50.6 million (2014).
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Change in Acquisitions & Divestments skyrocketed by 46070.73% in 2014 and then crashed by 8814.65% in 2018.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Change in Acquisitions & Divestments stood at $52.5 million in 2014, then grew by 23.26% to $64.7 million in 2015, then tumbled by 48.31% to $33.4 million in 2016, then fell by 16.99% to $27.8 million in 2017, then fell by 28.48% to $19.9 million in 2018.
  • Its last three reported values are $19.9 million in Q4 2018, $16.8 million for Q3 2018, and $13.9 million during Q2 2018.